NEWS Media Contacts: Europe Emmanuella Dekonor Mobile: +44 7920500496 Email: Emmanuella.Dekonor@seqirus.com United States Polina Miklush Mobile: +1 908 608 7170 Email: polina.miklush@seqirus.com Asia Pacific Ruth Heenan Mobile: +610416 565 332 Email: Ruth.Heenan@seqirus.com Seqirus news releases EU Flu Day 2021 – Seqirus joins experts’ calls to boost vaccine uptake ahead of a second influenza season during the COVID-19 pandemic 14 Oct 2021 • Expert modelling points to a more severe influenza season than in previous years.1 • The lifting of restrictions to reduce COVID-19 transmission may leave vulnerable people – with reduced immunity - at greater risk from influenza.1 • Co-administration of the seasonal influenza vaccine with the COVID-19 booster may not only protect vulnerable populations, it could also relieve the burden on healthcare systems. • A panel of leading international experts discuss the challenges of the oncoming influenza season at this year’s EU Flu Day, led by Vaccines Europe and supported by Seqirus. Read Release The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) Efficacy in Children and Adolescents ≥2 to <18 Years of Age 14 Oct 2021 Read Release Seqirus Awarded U.S. Government Contract to Develop Two Pandemic Influenza Vaccines 04 Oct 2021 • Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives • Company will utilize its combination of cell-based and adjuvanted influenza vaccine technologies, as well as its next-generation self-amplifying mRNA platform • Multi-year contract with Biomedical Advanced Research and Development Authority (BARDA) builds on longstanding, successful public-private partnership to provide rapid vaccine manufacturing response in an influenza pandemic Read Release Seqirus Announces Investment in Next-Generation Influenza Vaccine Technology, Self-Amplifying Messenger RNA (sa-mRNA) 19 Aug 2021 • Appoints Roberta Duncan as new program lead to drive technology advancement • Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza Read Release Seqirus Begins Shipping Portfolio of Innovative Vaccines for the 2021/22 U.S. Influenza Season 27 Jul 2021 The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic. Read Release Seqirus strengthens U.K. influenza vaccine response as high-speed fill and finish facility begins rolling 30 million doses in Liverpool 01 Jun 2021 First doses of Seqirus’s enhanced influenza vaccine, destined for the U.K., come off a new high-speed fill-and-finish line in Liverpool. Read Release Seqirus Presents New Late-Breaking Data at ESWI 2020 Highlighting Value of MF59®-Adjuvanted Seasonal Influenza Vaccine 14 Dec 2020 Read Release Seqirus Presents Real-World Data for Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) at ESWI 2020 14 Dec 2020 This news release is intended for Health Professional media only. Read Release Update on The University of Queensland COVID-19 vaccine 11 Dec 2020 Read Release Seqirus Will Build World-class, Next-generation $800m Influenza Vaccine Manufacturing Facility in Australia 16 Nov 2020 Read Release CSL Named as One of the World’s Best Employers 29 Oct 2020 Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year Read Release This EU Flu Day, Seqirus confirms record number of influenza vaccines delivered across Europe to meet increased demand 14 Oct 2020 The first annual EU Flu Day was launched today, 14 October 2020. Marking the occasion, Seqirus, a global leader in influenza prevention, announced that it has delivered shipments of influenza vaccines on schedule, across Europe Read Release CSL to manufacture and supply University of Queensland and Oxford University vaccine candidates for Australia 07 Sep 2020 CSL Limited (ASX:CSL) today announced it has signed a Heads of Agreement (HoA) with the Australian Government for the supply of 51 million doses of the University of Queensland’s (UQ) COVID-19 vaccine candidate (V451), and a separate HoA with AstraZeneca to manufacture the Oxford University candidate (AZD1222), should clinical trials of both prove successful. Read Release Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market 30 Jul 2020 Read more First adjuvanted quadrivalent influenza vaccine receives EU approval 08 Jun 2020 This news release is intended for medical, pharmaceutical industry and business media Read more The University of Queensland, CEPI and CSL partner to advance development and manufacture of COVID-19 vaccine candidate 05 Jun 2020 Read more The CSL Group collaborates with Global Plasma Leaders to accelerate development of potential COVID-19 Hyperimmune therapy 06 Apr 2020 Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19 Read more COVID-19 Update 03 Apr 2020 Safeguarding our people and communities remains our top priority. Read update Seqirus announces positive CHMP Opinion for its adjuvanted quadrivalent influenza vaccine 31 Mar 2020 This news release is intended for medical and pharmaceutical trade media and financial media only Read Release The CSL Group Offer To Help Battle Coronavirus 23 Mar 2020 To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing. Read more Load more Report an Adverse Event Cookie Policy Privacy Notice Modern Slavery Terms of Use Sitemap © 2021 Seqirus. All rights reserved. Seqirus is a trademark of Seqirus UK Limited or its affiliates. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookies Settings Reject All Accept All Cookies